These findings reveal a novel PABPC1-PGK1 regulatory axis underlying sunitinib resistance and suggest a promising therapeutic strategy for overcoming drug resistance in ccRCC. The gene discussed is PGK1; the disease is nonpapillary renal cell carcinoma.